Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Wendi CHENG"'
Autor:
Wendi CHENG, Xiao ZHANG, Zhaohui PAN, Youjun ZHAO, Chenguang SUN, Xueqiang SHAN, Yuzhan JIN, Xiaonan ZHAO
Publikováno v:
大数据, Vol 10, Pp 3-20 (2024)
With the development of measurement techniques and numerical simulation technologies, data-driven turbulence research has become a new approach in this field.In China, several wind tunnel laboratories and supercomputing centers have been established
Externí odkaz:
https://doaj.org/article/7e0e569bde15497d8789f4c658d8ff13
Autor:
Haode Wang, Hui Sun, Yuyan Fu, Wendi Cheng, Chunlin Jin, Hongcheng Shi, Yashuang Luo, Xinjie Xu, Haiyin Wang
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Importance Innovative nuclear medicine services offer substantial clinical value to patients. However, these advancements often come with high costs. Traditional payment strategies do not incentivize medical institutes to provide new service
Externí odkaz:
https://doaj.org/article/c826582c5b3246c6817cf0ac57e5615e
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 18, Iss 1, Pp 1-8 (2020)
Abstract Stereotactic body radiotherapy (SBRT) is a novel noninvasive treatment for hepatocellular carcinoma. SBRT can achieve effective local control, but it requires a relatively high input of resources; this systematic review was performed to asse
Externí odkaz:
https://doaj.org/article/18c28239231e48a9ac770bf4520e49dd
Autor:
Wendi Cheng1, Yifan Cao1, Hua Wang2, Xin Peng3, Chunyan Xie1, Changying Wang1, Duo Chen1, Lingshan Wan1, Jia Xue1, Yunwei Zhang1, Hongyun Xin1, Wei Zhuang4, Hansheng Ding1
Publikováno v:
BioScience Trends. Apr2023, Vol. 17 Issue 2, p177-182. 6p.
Autor:
Yunwei Zhang, Changying Wang, Xiaoyan Yu, Lingshan Wan, Wendi Cheng, Chunyan Xie, Duo Chen, Yifan Cao, Jia Xue, Yuhong Niu, Hansheng Ding
Publikováno v:
BioScience Trends. 17:172-176
Publikováno v:
BioScience Trends. 17:183-185
Publikováno v:
Blood Purif
Università degli Studi di Padova-IRIS
Università degli Studi di Padova-IRIS
Background: The maintenance treatment of ESRD puts a great burden on individual patients, society, and the country of China as a whole. Hemoperfusion plus hemodialysis (HP + HD) in ESRD patients can yield modified outcomes such as prolonged life expe
Publikováno v:
2021 IEEE 3rd International Conference on Frontiers Technology of Information and Computer (ICFTIC).
Publikováno v:
BioScience Trends. 13:110-116
As the reform of Chinese medical and health undertakings has advanced (since 2015), the admission, pricing and payment policies regarding the new health technologies of China have undergone significant changes, and health technology assessment (HTA)
Autor:
Wendi Cheng, Yuyan Fu, Mark Pennington, Chunlin Jin, Xin Liu, Gengru Jiang, Xiaoxiao Qin, Huajie Jin, Wei Lu, Haiyin Wang, Yashuang Luo
Publikováno v:
Ann Transl Med
King's College London
King's College London
Background This study evaluates the cost-effectiveness of hemodialysis (HD) plus hemoperfusion (HP) with HD alone in adult patients with end-stage renal disease (ESRD) in China. Methods A Markov model was constructed to assess the cost-effectiveness